Allan Wagman joined Rain Therapeutics in 2018 as vice president, head of technical operations where he leads chemistry research and chemistry, manufacturing and controls (CMC). Previously, he was senior director, head of chemistry and CMC at 3-V Biosciences which advanced a novel FASN inhibitor TVB-2640 into Phase 2 oncology and NASH studies. Allan began his pharmaceutical industry career at Chiron, which became a division of Novartis, where he worked on oncology, metabolism and infectious disease programsand then joined Achaogen as director of chemistry.

Allan earned a BS in organic chemistry at Carnegie-Mellon University, a PhD in synthetic organic chemistry and natural product synthesis at University of Texas at Austin, and performed postdoctoral research at the University of North Carolina at Chapel Hill.